Individuals with severe hemophilia B (<1% or <1IU/dL FIX activity) suffer from frequent spontaneous bleeds, resulting in chronic arthropathy and potentially life-threatening hemorrhages.1 The current standard of care, lifelong factor IX concentrate prophylaxis, while improving outcomes, remains invasive, costly, and burdensome.1 Here, F9 is linked to hemophilia B.